| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8574634 | NAPO PHARMS INC | Compositions and methods of treatment with proanthocyanidin polymer antidiarrheal compositions |
Jan, 2018
(6 years ago) | |
| US7323195 | NAPO PHARMS INC | Enteric formulations of proanthocyanidin polymer antidiarrheal compositions |
Jun, 2018
(5 years ago) | |
| US7341744 | NAPO PHARMS INC | Method of treating secretory diarrhea with enteric formulations of proanthocyanidin polymer |
Jun, 2022
(1 year, 10 months ago) | |
| US8962680 | NAPO PHARMS INC | Methods and compositions for treating HIV-associated diarrhea |
Oct, 2031
(7 years from now) | |
| US9585868 | NAPO PHARMS INC | Methods and compositions for treating HIV-associated diarrhea |
Oct, 2031
(7 years from now) | |
Mytesi is owned by Napo Pharms Inc.
Mytesi contains Crofelemer.
Mytesi has a total of 5 drug patents out of which 3 drug patents have expired.
Expired drug patents of Mytesi are:
- US8574634
- US7323195
- US7341744
Mytesi was authorised for market use on 31 December, 2012.
Mytesi is available in tablet, delayed release;oral dosage forms.
Mytesi can be used as symptomatic relief of non-infectious diarrhea.
Drug patent challenges can be filed against Mytesi from 31 December, 2016.
The generics of Mytesi are possible to be released after 31 October, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 31, 2017 |
Drugs and Companies using CROFELEMER ingredient
NCE-1 date: 31 December, 2016
Market Authorisation Date: 31 December, 2012
Treatment: Symptomatic relief of non-infectious diarrhea
Dosage: TABLET, DELAYED RELEASE;ORAL
MYTESI family patents
